ArticleScience advances2024
H
Abstract read
In one paragraph
Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- STAT3 interference-driven nanomodulators reverse lipid metabolism-associated chemoresistance and potentiate metalloimmunotherapy in breast cancer.Cell reports. Medicine · 2026Article
- The role of Dymeclin in chronic unpredictable mild stress-induced depression: maintaining the Golgi apparatus structure and regulating NLRP3 inflammasome activation.Molecular medicine (Cambridge, Mass.) · 2026Article
- Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Targeting organelle function in T cells for cancer immunotherapy.Nature reviews. Immunology · 2026Review
- Spatiotemporal dynamics of reactive oxygen species: implications for cellular homeostasis and redox therapies.Cellular & molecular biology letters · 2026Review
- Reactive sulfur species as emerging immunomodulators: mechanistic insights and therapeutic prospects.Frontiers in immunology · 2026Review
- HFrontiers in cell and developmental biology · 2026Review
- Gas-mediated reinforcement of cancer therapies: emerging strategies and future perspectives.Chemical science · 2025Review
- Alzheimer's Disease-Associated Amyloid-β Precursor Protein Prevents Aging Stress-Induced Mitophagy and Fumarate Depletion to Improve Antitumor Immunity.Cancer research · 2025Article
- Tailoring Tumor Cell Golgi Apparatus-Targeting Self-Assembled Peptide for Effective Immunotherapy via Reshaping MIF-Mediated Immunosuppressive Network.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Nathaniel OberholtzerDepartment of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-9080-5130
Paramita ChakrabortyDepartment of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
Mohamed Faisal KassirDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0003-3501-1802
James DressmanDepartment of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-6659-6367
Satyajit DasDepartment of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
Stephanie MillsDepartment of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-1478-8033
Susana Comte-WaltersDepartment of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC 29425, USA.
Monika GoozDepartment of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0001-6404-5070
Seungho ChoiDepartment of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
Rasesh Y ParikhDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-6298-870X
Zacharia HedleyDepartment of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
Silvia VaenaTranslational Science Laboratory, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Reid DeMassDepartment of Public Health, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-8859-600X
Gina ScurtiDepartment of Surgery, Loyola University, Chicago, IL 60153, USA.
Martin RomeoTranslational Science Laboratory, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0001-7941-1862
Vamsi K GangarajuDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0003-3498-6624
Stefano BertoDepartment of Neuroscience, Medical University of South Carolina, Charleston, SC 29425, USA.
Elizabeth HillDepartment of Public Health, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0003-0896-4106
Lauren E BallDepartment of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0001-6780-1679
Anand S MehtaDepartment of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC 29425, USA.
Eduardo N MaldonadoDepartment of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-5285-3027
Michael I NishimuraDepartment of Surgery, Loyola University, Chicago, IL 60153, USA.
Besim OgretmenDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-1019-5660
Shikhar MehrotraDepartment of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-5411-9504
Funding
Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J Lemasters · 2009 to 2026
$42.7MProteomics CoreP30DK123704 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Garth R Swanson · 2020 to 2026
$8.8MCeramide Signaling in the Regulation of Head & Neck Cancer Cell Death and TherapyR01DE016572 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI OGRETMEN, BESIM · 2005 to 2025
$7.4MSouth Carolina COBRE in Oxidants, Redox Balance and Stress SignalingP30GM140964 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI EBLEN, SCOTT T · 2021 to 2025
$6.4MResearch Supplement to Promote Diversity in Health-Related ResearchR01CA214461 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Besim Ogretmen · 2018 to 2026
$3.3MAnti-oxidant and Metabolic Phenotype in Regulating Tumor Specific T cell Memory ResponseR01CA236379 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MEHROTRA, SHIKHAR · 2020 to 2024
$2.5MUnderstanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cellsR01CA250458 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MEHROTRA, SHIKHAR · 2020 to 2024
$2.3MProgramming Metabolically Fit TILs for ImmunotherapyR42CA239952 · NCI · LIPO-IMMUNO TECH, LLC · PI MEHROTRA, SHIKHAR · 2023 to 2024
$2.0MRegulation of piRNA pathway by the Nuclear Pore ComplexR01GM130846 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GANGARAJU, VAMSI · 2019 to 2023
$1.6MOrbitrap Fusion Lumos ETD Mass SpectrometerS10OD025126 · OD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BALL, LAUREN ELIZABETH · 2018 to 2018
$991kConfocal/Multiphoton Microscope UpgradeS10OD018113 · OD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LEMASTERS, JOHN J · 2015 to 2015
$570kIncreasing Thiols for Improving T cell ImmunotherapyR41CA271958 · NCI · LIPO-IMMUNO TECH, LLC · PI MEHROTRA, SHIKHAR · 2022 to 2022
$394kNCI NIH HHS P30 CA138313NCI NIH HHS R01 CA214461NCI NIH HHS R01 CA236379NCI NIH HHS R01 CA250458NCI NIH HHS R41 CA271958NCI NIH HHS R42 CA239952NIDCR NIH HHS R01 DE016572NIDDK NIH HHS P30 DK123704NIGMS NIH HHS P30 GM140964NIGMS NIH HHS R01 GM130846NIH HHS S10 OD018113NIH HHS S10 OD025126
Abstract
The role of tumor microenvironment (TME)-associated inadequate protein modification and trafficking due to insufficiency in Golgi function, leading to Golgi stress, in the regulation of T cell function is largely unknown. Here, we show that disruption of Golgi architecture under TME stress, identified by the decreased expression of GM130, was reverted upon treatment with hydrogen sulfide (H
Indexed as
Golgi ApparatusHydrogen SulfideT-LymphocytesTumor MicroenvironmentAnimalsCell Line, TumorCystathionine beta-SynthaseHumansImmunotherapyMiceStress, PhysiologicalCystathionine beta-SynthaseHydrogen Sulfide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.